Current Atherosclerosis Reports

, Volume 11, Issue 4, pp 301–308 | Cite as

Chronic kidney disease and statins: Improving cardiovascular outcomes

  • D. Benson Walker
  • Thanh Jennifer Walker
  • Terry A. Jacobson


The burden of chronic kidney disease (CKD) continues to increase worldwide. Patients with CKD are at greater risk of mortality from cardiovascular events than end-stage renal disease. This review describes the pathogenesis of dyslipidemia in CKD patients and the role of statins in reducing coronary heart disease morbidity and mortality. The major clinical trials with statins in CKD patients are reviewed along with a discussion of statin safety. Although statin dosing and safety in patients with early CKD (Stage I or II) are similar to those of the general population, dose adjustments are required in advanced CKD (Stages III–V) due to differences in statin pharmacokinetics and renal excretion. Although the use of statins to reduce cardiovascular events in patients with mild to moderate CKD is strongly supported by existing clinical trials, no clinical benefit has been demonstrated in two large clinical trials involving hemodialysis patients.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sarnak MJ, Levey AS, Schoolwerth, et al.: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154–2169.PubMedCrossRefGoogle Scholar
  2. 2.
    Rashidi A, Sehgal AR, Rahman M, et al.: The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008, 102:1668–1673.PubMedCrossRefGoogle Scholar
  3. 3.
    Tonelli M, Wiebe N, Culleton B, et al.: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034–2047.PubMedCrossRefGoogle Scholar
  4. 4.
    Parfrey PS, Foley RN, Harnett JD, et al.: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996, 49:1428–1434.PubMedCrossRefGoogle Scholar
  5. 5.
    Muntner P, He J, Astor BC, et al.: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005, 16:529–538.PubMedCrossRefGoogle Scholar
  6. 6.
    National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1–S266.Google Scholar
  7. 7.
    Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006, 290:262–272.CrossRefGoogle Scholar
  8. 8.
    Chan DT, Irish AB, Dogra GK, et al.: Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008, 196:823–834.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheung AK, Parker CJ, Ren K, et al.: Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996, 49:1360–1371.PubMedCrossRefGoogle Scholar
  10. 10.
    Prinsen BH, De Sain-Van Der Velden MG, de Koning EJ, et al.: Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003, S121–S124.Google Scholar
  11. 11.
    Diercks GF, Janssen WM, Van Boven AJ, et al.: Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease With fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000, 86:635–638.PubMedCrossRefGoogle Scholar
  12. 12.
    Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.PubMedCrossRefGoogle Scholar
  13. 13.
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.CrossRefGoogle Scholar
  14. 14.
    Tonelli M, Isles C, Craven T, et al.: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005, 112:171–178.PubMedCrossRefGoogle Scholar
  15. 15.
    Tonelli M, Moye L, Sacks FM, et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98–104.PubMedGoogle Scholar
  16. 16.
    Shepherd J, Kastelein JJ, Bittner V, et al.: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. J Am Coll Cardiol 2008, 51:1448–1454.PubMedCrossRefGoogle Scholar
  17. 17.
    Shepherd J, Kastelein JJ, Bittner V, et al.: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008, 83:870–879.PubMedCrossRefGoogle Scholar
  18. 18.
    Holdaas H, Fellstrom B, Jardine AG, et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024–2031.PubMedCrossRefGoogle Scholar
  19. 19.
    Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.PubMedCrossRefGoogle Scholar
  20. 20.
    Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395–1407.PubMedCrossRefGoogle Scholar
  21. 21.
    Seliger SL, Weiss NS, Gillen DL, et al.: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002, 61:297–304.PubMedCrossRefGoogle Scholar
  22. 22.
    Andreucci VE, Fissell RB, Bragg-Gresham JL, et al.: Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004, 44:S61–S67.CrossRefGoogle Scholar
  23. 23.
    Baigent C, Landry M: Study of heart and renal protection. Kidney Int 2003, 63:S207–S210.CrossRefGoogle Scholar
  24. 24.
    Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol 1994, 73:3D–11D.PubMedCrossRefGoogle Scholar
  25. 25.
    Harper CR, Jacobson TA.: Treatment of dyslipidemia in CKD. J Am Coll Cardiol 2008, 51:2375–2384.PubMedCrossRefGoogle Scholar
  26. 26.
    Koren MJ, Davidson MH: Impact of aggressive treatment with atorvastatin in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract]. J Am Coll Cardiol 2005, 45(Suppl A):391AGoogle Scholar
  27. 27.
    K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis 2003, 41(Suppl 3):S1–S237.Google Scholar
  28. 28.
    National Cholesterol Education Program Expert Panel on Detection: Third report of the National Cholesterol Education Program (NCEP)Expert Panel on detection, evaluation, and treatment of High blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–421.Google Scholar
  29. 29.
    Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report From the American Diabetes Association and the American College of Cardiology. J Am Coll Cardiol 2008, 51(15):1512–1524.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • D. Benson Walker
  • Thanh Jennifer Walker
  • Terry A. Jacobson
    • 1
  1. 1.Office of Health Promotion and Disease PreventionAtlantaUSA

Personalised recommendations